Open company graph database — free web & API
Login

Takara Bio Inc.

タカラバイオ株式会社
Ticker
—
Listed market
TYO
Country
Japan
Employees (consolidated)
1,743
Related companies
11
§01

Basic information

BASIC
Head office
4-38, Higashi-nishi 7-chome, Kusatsu City, Shiga Prefecture, Japan
Chief executive
Takeshi Miyamura
Capital
14,965,828,496  (149 100 million)
Employees (non-consolidated)
764 people
Employees (consolidated)
1,743 people
Start date
2002-04-01
End date
§02

Websites

1 DOMAINS
§03

Business

0
§04

Related companies

11 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Takara Bio Europe S.A.S.
Group
Takara Bio USA, Inc.
Group
Takara Korea Biomedical Inc.
Group
Bao Sheng Biotechnology (Dalian) Co., Ltd.
Group
DSS Takara Bio India Pvt. Ltd.
Group
Baori Medical Biotechnology (Beijing) Co., Ltd.
Group
DSS Imagetech Pvt. Ltd.
Shareholder
Takara Bio Europe AB
Takara Bio USA Holdings Inc.
Toyota Motor Corporation
Takaraholdings Co., Ltd.
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

39 EVENTS

Establishment of Takara Brewery Co., Ltd.Sources

Central Research Laboratory completed in Otsu City, Shiga PrefectureSources

Developed and commercialized artificial cultivation method for Bunan shiimejiSources

Released Japan's first domestically produced genetic engineering research reagent "restriction enzymes": Commenced bio businessSources

Obtained exclusive domestic sales rights for PCR-based gene amplification systemSources

Acquired extensive global PCR-related patent licenses and began in-house production of PCR productsSources

Established Takara Bio Engineering (Dalian) Co., Ltd. in Dalian, China, for manufacturing bio research reagentsSources

Established Takara Bio Europe S.A.S. in Paris, France, for selling bio research reagentsSources

Developed high-efficiency gene transfer method "RetroNectin" for hematopoietic stem cellsSources

Established Bohan Biomedical Inc. (now Takara Korea Biomedical Inc.) in Seoul, South KoreaSources

Established Dragon Genomics Co., Ltd.: Fully entered gene analysis services (absorbed by Takara Bio in 2002)Sources

Established Mizuhonourin Co., Ltd. (transferred to Yuki Kuni Maitake Co., Ltd. in 2019)Sources

Takara Brewery Co., Ltd. spun off: transitioned to holding structure and renamed to Takara Holdings Co., Ltd.; established Takara Brewery Co., Ltd. and Takara Bio Inc.Sources

Established: April 1, 2002Sources

EstablishedSources

Established Takara Bio Technology (Beijing) Co., Ltd. in Beijing, ChinaSources

Listed shares on Tokyo Stock Exchange MothersSources

Acquired management rights of Clontech Laboratories, Inc. (now Takara Bio USA, Inc.) in the United StatesSources

Established Kinoshita Center Kinmu Co., Ltd. subsidiary in Okinawa Prefecture (transferred to Yuki Kuni Maitake Co., Ltd. in 2019)Sources

Established DSS Takara Bio India Private Limited subsidiary in New Delhi, IndiaSources

Acquired all shares of Cellectis AB in Yotebori City, Sweden, making it a subsidiary and renamed it Takara Bio Europe AB.Sources

Completed the Gene and Cell Processing Center in Kusatsu City, Shiga Prefecture: Commenced full‑scale CDMO operations providing development and manufacturing support services for regenerative medicine products and gene therapies.Sources

Completed a new headquarters building in Kusatsu City, Shiga Prefecture, and relocated headquarters functions there.Sources

Changed market listing from Tokyo Stock Exchange Mothers to the First Section of the same market.Sources

Subsidiary Takara Bio USA Holdings, Inc. acquired all shares of Rubicon Genomics, Inc., and subsequently merged into Takara Bio USA, Inc.Sources

Subsidiary Takara Bio USA Holdings, Inc. acquired all shares of WaferGen Bio‑systems, Inc., and subsequently merged into Takara Bio USA, Inc.Sources

The NY‑ESO‑1/siTCR gene therapy for synovial sarcoma (development code: TBI‑1301) was designated as a subject item under the Ministry of Health, Labour and Welfare's "Accelerated Review Designation System."Sources

Transferred the health food business to Shionogi Healthcare Co., Ltd.Sources

Transferred the mushroom business to Snow Country Maitake Co., Ltd.Sources

Gene and Cell Processing Center Building 2 commenced operations.Sources

Released the in vitro diagnostic drug "Takara SARS‑CoV‑2 Direct PCR Kit."Sources

The NY‑ESO‑1/siTCR gene therapy (development code: TBI‑1301) was designated as a regenerative medicine product for rare diseases.Sources

Established Takara Bio UK Ltd.Sources

Relocated the headquarters of Takara Bio USA Inc. to San Jose, California, USA.Sources

Changed listing from the First Section to the Prime Market of the Tokyo Stock Exchange due to a review of market classifications.Sources

Merged Takara Bio Europe AB into Takara Bio Europe S.A.S., which remained the surviving company.Sources

Commenced construction of Gene and Cell Processing Center Building 3.Sources

Subsidiary Takara Bio USA Holdings, Inc. acquired all shares of Curio Bioscience, Inc., a developer of spatial transcriptomics assay reagents, and made it a subsidiary.Sources

Acquired all shares of ViSpot Co., Ltd., which provides virus safety assessment testing services, and subsequently merged it.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information1160001002490
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
タカラバイオ株式会社
Trade name (kana)
タカラバイオ
Name in English
Corporation type
301
Address
〒525-0058 滋賀県草津市野路東7丁目4番38号
Postal code
5250058
Prefecture code
25
City code
206
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2025-05-12
Change date
2025-05-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
令和7年5月1日神戸市中央区港島南町六丁目3番5号ViSpot株式会社(4140001107685)を合併
Latest record
1
Excluded from search
0
Processing type
71
Correction type
0
Trade name image ID
Address image ID
Sequence number
3825775
METI gBizINFO1160001002490
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1160001002490
Trade name
タカラバイオ株式会社
Trade name (kana)
タカラバイオ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
滋賀県草津市野路東7丁目4番38号
Postal code
5250058
Prefecture
滋賀県
Prefecture code
25
City or district
草津市
City code
206
Street address
野路東7丁目4番38号
Organisation type
301
Processing type
71
Correction type
0
Status
Representative
代表取締役社長 仲尾 功一
Capital
14965000000
Employees
800
Employees (male)
Employees (female)
Business summary
研究用試薬、理化学機器の開発製造販売、再生医療等製品の開発製造支援サービス、遺伝子解析受託サービス、遺伝子治療の臨床開発
Website URL
http://www.takara-bio.co.jp/
Year founded
Business category
E:製造業
Date established
2002-04-01
Unified government qualification - grade
A|A|A|
Unified government qualification - business items
122|129|202|207|217|218|219|221|222|229|303|304|315
Update date
2025-05-12
Key information
1160001002490
§09

Sources & updates

SOURCES
↑